8-KOther Events

Edwards Lifesciences Corp 8-K Report (Oct 30, 2003)

Filed October 30, 2003For Securities:EW

Summary

Edwards Lifesciences Corporation (EW) filed an 8-K on October 29, 2003, primarily to provide investors with a reconciliation of non-GAAP financial measures previously included in their 2002 Form 10-K. These non-GAAP measures are presented to offer a more comparable view of the company's financial performance across different periods, particularly concerning the "Japan business" and certain product lines. The filing details several non-GAAP metrics, including international sales growth, total and product-line net sales, gross profit, Selling, General & Administrative (SG&A) expenses, and Research & Development (R&D) expenses. The "pro forma" adjustments aim to reflect scenarios where the Japan business was consolidated for all periods presented and to account for the impact of foreign currency fluctuations, as well as the assumed earlier commencement of sales for specific product lines (mechanical cardiac assist, perfusion, and perfusion services). This supplemental information is intended to provide investors with a clearer understanding of underlying business trends and operational performance.

Key Highlights

  • 1Edwards Lifesciences filed an 8-K on October 29, 2003, to provide reconciliations for non-GAAP financial measures.
  • 2The filing includes detailed reconciliations for international sales growth, accounting for the Japan business consolidation and currency impacts.
  • 3Pro forma net sales and product-line sales data are presented, assuming the Japan business was consolidated across all periods.
  • 4The company also provided pro forma gross profit, SG&A, and R&D expenses as a percentage of net sales.
  • 5These adjustments were made to reflect hypothetical scenarios for comparative financial analysis, particularly for fiscal years 2000, 2001, and 2002.
  • 6The filing aims to offer investors a more consistent view of performance by adjusting for business consolidations and currency fluctuations.
  • 7Corinne H. Lyle, Corporate Vice President, Chief Financial Officer, and Treasurer, signed the report.

Frequently Asked Questions

The primary purpose of this 8-K filing is to provide investors with detailed reconciliations of certain non-GAAP financial measures that were previously reported in Edwards Lifesciences' 2002 Form 10-K. These reconciliations are intended to clarify the adjustments made for comparative financial analysis, especially concerning the consolidation of the Japan business and currency exchange rate impacts.

The filing details adjustments to international sales (including and excluding currency impacts), total net sales and net sales by product line, gross profit as a percentage of net sales, Selling, General & Administrative (SG&A) expenses as a percentage of net sales, and Research and Development (R&D) expenses as a percentage of net sales. These adjustments are presented for the years 2000, 2001, and 2002.

Presenting the 'Japan business' as consolidated for all periods aims to provide a more consistent and comparable view of the company's financial performance across different reporting periods. This hypothetical consolidation helps investors understand the underlying revenue and profitability trends without the distortion of differing consolidation dates or the impact of acquiring or consolidating businesses at different times.

No, these non-GAAP measures are supplemental and are presented alongside the official GAAP financial statements. The purpose of these non-GAAP measures and their reconciliations is to offer investors additional insights into the company's operational performance by isolating specific factors like business consolidation and currency fluctuations, thereby allowing for a clearer comparison of trends.